Rohto Pharmaceutical Co.,Ltd.
4527
주식 순위
#3856
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global... Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their comprehensive product line includes various ophthalmic solutions such as eye drops, contact lens care products, and eye washes. For skincare, they offer facial treatments like cleansers, toners, and creams, in addition to specialized medicated preparations for the skin. The company's offerings also extend to internal medicines, encompassing digestive aids, herbal remedies, and dietary supplements. Furthermore, they supply over-the-counter medications and deliver beauty and health services via dedicated counters. The company rebranded from Yamada Pharmaceutical to Rohto Pharmaceutical Co.,Ltd. in September 1949.
주가
$19.03
시가총액
$4.30B
변동 (1일)
0.15%
변동 (1년)
16.15%
국가
JP
거래 Rohto Pharmaceutical Co.,Ltd. (4527)
카테고리
Consumer Defensive
Rohto Pharmaceutical Co.,Ltd. (4527)의 수익
Jun 2026 기준 수익 TTM: $303.71M
Rohto Pharmaceutical Co.,Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $303.71M입니다. 2024년에 회사는 $274.31M의 수익을 올렸으며 이는 2023년의 수익 $258.26M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Rohto Pharmaceutical Co.,Ltd.의 수익 기록 (2008 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $303.71M | 7.55% |
| 2025 | $282.40M | 2.95% |
| 2024 | $274.31M | 6.21% |
| 2023 | $258.26M | 12.49% |
| 2022 | $229.58M | 10.53% |
| 2021 | $207.71M | 2.77% |
| 2020 | $202.12M | 37.64% |
| 2019 | $146.85M | -7.24% |
| 2018 | $158.31M | 19.53% |
| 2017 | $132.44M | 4.19% |
| 2016 | $127.12M | 10.88% |
| 2015 | $114.65M | -19.00% |
| 2014 | $141.54M | -2.14% |
| 2013 | $144.64M | -14.82% |
| 2012 | $169.81M | 4.81% |
| 2011 | $162.02M | 21.98% |
| 2010 | $132.83M | 41.40% |
| 2009 | $93.94M | -24.26% |
| 2008 | $124.03M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $20.38B | 6,609.37% |
US
|
|
| $9.83B | 3,135.44% |
FR
|
|
| $2.94B | 868.36% |
US
|
|
| $1.55B | 410.35% |
IN
|
|
| $517.00M | 70.23% |
US
|
